Coronavirus disease 2019

[키워드] Academy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adult patients Adverse adverse event adverse events Analysis animal models antiviral drug arterial oxygen partial pressure assigned Beijing breath China Chinese clinical benefits Clinical improvement clinical status concomitant use confirmation coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 defined development discharged double-blind effective Eligible patients Emergency enrolled enrolment event faster followed by fractional inspired oxygen GS-5734 hazard ratio hospital human coronaviruses in vitro inhibit inhibitory effect Inhibitory effects intention-to-treat interferons Intravenous remdesivir ITT ITT population laboratory-confirmed SARS-CoV-2 infection less Lopinavir Lopinavir-ritonavir Medical Science Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus multicentre nucleoside one patient Ordinal Scale oxygen oxygen partial pressure oxygen saturation partial pressure pathogenic Patient Placebo placebo group placebo recipients placebo-controlled Pneumonia primary analysis primary endpoint Program randomisation randomised Randomly receiving recipient reduction in Registered Remdesivir reported research and development respiratory respiratory syndrome coronavirus Ritonavir room air safety analysis SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication Science severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 statistically significant symptom duration symptom onset technology the placebo group those receiving placebo treated Treatment treatment group Trial Volume was done
[DOI] 10.1016/S0140-6736(20)31022-9 PMC 바로가기 [Article Type] Randomized Controlled Trial